synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
==== Attention deficit hyperactivity disorder ==== Modafinil is occasionally prescribed off-label for individuals with attention deficit hyperactivity disorder (ADHD). It has not consistently shown efficacy in treating adult ADHD, especially when compared to other treatments such as lisdexamfetamine. In children, modafinil shows efficacy for ADHD symptoms in clinical trials, though it is less effective than first-line treatments such as methylphenidate and amphetamines. Modafinil was investigated for ADHD because of its lower abuse potential than conventional psychostimulants, but evidence for adult ADHD is mixed. A 2016 systematic review did not recommend its use, and a large Phase III trial found modafinil ineffective with a high rate of side effects (86%) and discontinuation (47%), possibly due to high doses (210–510 mg/d). A 2008 US Food and Drug Administration application for pediatric ADHD was denied due to concerns about rare but serious dermatological toxicity. Modafinil is considered a second-line treatment for comorbid ADHD and bipolar disorder, after psychostimulants and bupropion.
=== 10 January === The SAF retook the town of Um al-Qura in Gezira State, 40 kilometers east of Wad Madani, from the RSF, while the SAF-allied Sudan Shield Forces retook Wad al-Abyad, 20 kilometres from the Hantoub bridge. At least 26 people were killed in an attack by the Sudan Shield Forces on the village of Tayba in Gezira State.
===== Interviews ===== The interview process involves separate interviews at hospitals around the country. Frequently, the individual applicant pays for travel and lodging expenses, but some programs may subsidize applicants' expenses.
Sources: en.wikipedia.org
Increased activity of the mitochondrial enzyme aldehyde dehydrogenase 2 (ALDH2) has been shown to have a protective effect against cardiac ischemia in animal models, and the postulated mechanism given by the investigators was 4-hydroxynonenal metabolism.
=== Main === Ben Feldman as Avi Schwooper, the oldest of the Schwooper children. Born in 1982 and growing up in Mountain View, California with his siblings, Avi has extensive knowledge of pop culture and music; he works as a review columnist and, by 2021, for a music streaming service. Avi is grounded and witty, but also cynical and passive in conflict. Avi starts dating Jen in 2004, and they later marry and have a daughter named Hannah, residing in Santa Rosa, California. By the 2010s, their relationship begins to break down, and they divorce in 2020, sharing custody of the now-teenage Hannah. In his adult years, Avi distances himself from his Jewish religious heritage, and is shown to be unable to tell his family he loves them, rather saying "Hey…y’know?" to indicate it. Avi suffers from pattern hair loss. Angelique Cabral as Jen Schwooper, Avi's non-Jewish girlfriend and later wife, born in 1983. Jen and Avi divorced in 2020, due to Naomi's passive aggression toward her and undermining her, and Avi's parenting. Avi struggled to stand up for himself and others and was cynical, and they grew apart. Jen majored in acting, but after the stress of putting on several failed plays in New York with her friends, Jen secretly wishes for a more regular job. Jen agrees to move to California after Avi is offered a music-journalism internship, though it is hinted she is ashamed she gave up acting. While it’s implied she helps with the theatre at Hannah's school in 2014, by 2019 Jen becomes a lucrative wine salesperson.
== Plot == A doctor informs fourth grader Eric Cartman and his mother Liane that his obesity is a threat to his health. When Liane says that proper diet and exercise has not worked for him, the doctor recommends a diabetes drug called semaglutide, which has been shown to help people lose weight. This prompts Cartman to fantasize about being able to viciously insult people with impunity without fear of being mocked for his weight, and even going all the way to Pakistan to continue this. However, insurance companies only cover the drug for diabetes, and are too expensive for Liane. The doctor prescribes that Cartman listen to the music of Lizzo, who frequently encourages body positivity. This leaves Cartman despondent, so his friends, Butters Stotch and Kyle Broflovski, accompany him to an insurance company office. However, when they request to make a claim with a dejected-looking claims officer, they are sent on a labyrinthine journey through the bureaucracy of the American health care system. They ultimately decide to make it themselves after learning the raw semaglutide powder can be purchased cheaply from a factory in India and mixed with biostatic water purchased locally. Their other friends, Stan Marsh and Kenny McCormick, join them in this scheme. Meanwhile, Randy Marsh observes many local mothers wearing crop-tops after attaining toned midriffs after losing weight with semaglutide, a recurring visual gag in the episode.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.